MARATTO

article · Journal of Medical and Life Science

Evaluation of AFP for diagnosis of HCC in Egyptian patients

20234 citationsOpen accessUniversity of Sadat City

Abstract

Background: It was initially suggested in the 1960s to use AFP as a tumor marker for hepatocellular carcinoma (HCC), AFP still plays a big part in HCC monitoring. Patients and methods: this study was conducted on 90 patients with liver diseases and 25 healthy control G1, patients were divided into 4 groups, (G2) 25 patients with HCV infection, (G3) 25 HCC+HCV infection, (G4) 25 patients with HBV infection, (G5) 15 patients with HCC + HBV. Results: there was a statistically significant difference between the five groups p-value >0.001*, compared to the control group the three groups G2, G3, and G5 have the same statistically significant difference with the same p-value >0.001*, while group 4 HBV patients have not statistically significant difference with p-value 0.254 compared to the control group, Serum AFP highly significant elevated in HCC patients associated with HCV or HBV infection patients.

Research topics

  • Liver Disease Diagnosis and Treatment

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/jmals.2023.329306

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.